Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT07115004 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Von Willebrand Disease (VWD)

Interventions

DRUG: VGA039

Sponsor

Vega Therapeutics, Inc